Managing thromboembolic risk with menopausal hormone therapy and hormonal contraception in the COVID-19 pandemic: recommendations from the Spanish Menopause Society, Sociedad Española de Ginecología y Obstetricia and Sociedad Española de Trombosis y Hemostasia. Ramírez, Isabel de la Viuda, Esther Baquedano Mainar, Laura Coronado, Pluvio Llaneza, Plácido Mendoza Ladrón De Guevara, Nicolás Otero, Borja Sánchez, Sonia Cancelo, Mª Jesús Páramo, José Antonio Cano, Antonio COVID-19 Hormone menopause therapy Venous thromboembolism prophylaxis COVID-19 is associated with a systemic inflammatory response with activation of coagulation in symptomatic patients. The possibility of coagulopathies in peri- and postmenopausal women taking estrogen therapies makes it necessary to consider antithrombotic strategies, such as the use of low molecular weight heparins (LMWH) at specific prophylactic or treatment doses for each individual case, depending on the risk factors that each woman presents. For such reasons, a panel of experts from various Spanish scientific societies has met to develop usage recommendations for managing menopausal women taking menopausal hormone therapy (MHT) or combined hormonal contraception (CHC) during the COVID-19 pandemic. 2025-01-14T08:03:59Z 2025-01-14T08:03:59Z 2020 journal article Ramírez I De la Viuda E, Baquedano L, Coronado P,Llaneza P, Mendoza N, Otero B, Sánchez S, Cancelo MJ, Páramoc JA, Cano A. Managing thromboembolic risk with menopausal hormone therapy and hormonal contraception in the COVID-19 pandemic: recommendations from the Spanish Menopause Society, Sociedad Española de Ginecología y Obstetricia and Sociedad Española de Trombosis y Hemostasia. Maturitas. 2020 Jul;137:57-62. doi: 10.1016/j.maturitas.2020.04.019. Epub 2020 https://hdl.handle.net/10481/99051 doi: 10.1016/j.maturitas.2020.04.019. eng http://creativecommons.org/licenses/by-nc-nd/3.0/ open access Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License Elsevier